Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 5
Abstract
Background and aims. Patients with intrahepatic cholestasis of pregnancy (ICP) benefit from ursodeoxycholic acid (UDCA) treatment. Since there is still certain reluctance to use UDCA in pregnant women, mainly due to warnings in the official SPC information in respective drug leaflets, our objective was to assess the efficacy and safety of UDCA during pregnancy. Material and methods. Our retrospective multicentric study was performed on 191 consecutive pregnant women with ICP treated with UDCA. Any maternal and/or fetal complications of the UDCA treatment were searched for; healthy pregnant women (n = 256) served as controls. Results. The UDCA treatment improved liver disease status in the majority of the affected women (86.1%). This treatment was well tolerated, with only negligible skin reactions (0.5%) and mild diarrhea (4.7%). No complications attributable to UDCA treatment were detected during the fetal life, delivery, or the early neonatal period. Conclusion. We confirmed the good efficacy and safety of UDCA treatment in pregnancy for both mothers and fetuses/neonates.
Authors and Affiliations
Antonín Parízek, Patrik Simják, Andrej Cerný, Alena Sestinová, Anna Zdenková, Martin Hill, Michaela Dusková, Radovan Vlk, Zuzana Kokrdová, Michal Koucký, Libor Vítek
Keywords
Related Articles
- EP ID EP78621
- DOI 10.5604/16652681.1212562
- Views 152
- Downloads 0
Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal stat
Introduction. Liver disease is a major health issue in Mexico. Although several studies have been performed to analyze the impact of liver diseases on the Mexican population, none has compared the prevalence and impact o...
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial eval...
Drug induced liver injury: accuracy of diagnosis in published reports
The diagnosis of drug induced liver injury (DILI) is based primarily on the exclusion of alternative causes. To assess the frequency of alternative causes in initially suspected DILI cases, we searched the Medline databa...
Mean platelet volume is a useful indicator of systemic inflammation in cirrhotic patients with ascitic fluid infection
Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease